Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
about
Pharmacokinetic characteristics of therapeutic antibodies.Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsMechanistic determinants of biotherapeutics absorption following SC administration.Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Golimumab - a new tool in the armoury against inflammatory arthritis.Intravenous golimumab in rheumatoid arthritis.Golimumab for treatment of axial spondyloarthritis.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites.Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.Mechanism of immunopotentiation and safety of aluminum adjuvants.Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.A review on golimumab in the treatment of psoriatic arthritis.
P2860
Q30316517-AF01F950-3E0E-4A46-991E-81CC2368BD94Q33956485-2D2CD2C8-1744-463E-A540-7C308E13E995Q34275537-D1DA4746-EFEC-46ED-A9F2-03B7C970966CQ36065572-95255312-DBC9-49F8-A67E-5F0C68BE8EE5Q37337375-0538B5F3-3D4C-412D-A5F8-78AB3C0B79FBQ37786627-1D51918C-009C-47CC-9C82-C3E0676B4A02Q37829741-DD95EC21-73AF-478F-92E8-CC8830115FE3Q38211958-4248B582-8AEA-458A-9CED-DE1064D528ECQ38707718-ED9D7E66-D349-4285-98FD-914B6564355DQ38714339-A2CD85AC-C22B-4D63-9F63-A18063A1B293Q38856947-93A833EA-EDCD-4377-AC93-0CFD5B7140F1Q39810650-C9D29C8A-C41C-45D4-B82F-6E11171E533CQ39816043-A8B40059-A28D-4E20-91E8-778919F6690AQ42036323-334036EC-04B8-4F70-BF27-54E23AE187E1Q45365263-C5EA92F6-E83D-4311-B333-D1E696B02137Q50034109-EAED7FD6-30D3-4035-89FB-BF6C68AFEB21Q51600613-D3117B85-467F-483D-AC9E-852DFD74A4DAQ53098976-C9ED6BC6-DA8D-48B9-89CF-8B9BD6C4CB47
P2860
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@ast
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@en
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@nl
type
label
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@ast
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@en
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@nl
prefLabel
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@ast
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@en
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@nl
P2093
P2860
P356
P1476
Subcutaneous bioavailability o ...... ion sites in healthy subjects.
@en
P2093
Bart Frederick
David Snead
Esther Bouman-Thio
Honghui Zhou
Hugh M Davis
Joseph C Marini
Monica Keen
Qingmin Wang
Yanli Zhuang
P2860
P304
P356
10.1177/0091270009340782
P577
2009-11-25T00:00:00Z